SIFI Secures European Patent for Innovative Polihexanide Formulation in Germany Eye Infection Treatment

The company's intellectual property ("IP") covers the formulation and method of use of polihexanide in the treatment of acanthamoeba keratitis and fung...

September 30, 2024 | Monday | News
Phase 3 CEPHEUS Study Shows 60.9% MRD-Negativity Rate and 43% Reduction in Risk of Progression or Death in Multiple Myeloma

Study demonstrates a minimal residual disease (MRD)-negativity rate of 60.9 percent and 43 percent reduction in the risk of progression or death1 Phase ...

September 30, 2024 | Monday | News
Enliven Therapeutics Reports Promising 44% MMR Rate at 24 Weeks in Phase 1 CML Trial for ELVN-001

Reported cumulative MMR rate of 44% by 24 weeks, with stable or deepening responses between weeks 12 and 24, continuing to surpass prior Phase 1 trials o...

September 30, 2024 | Monday | News
Takara Bio Europe Launches Shasta™ Single-Cell System, Advancing High-Throughput Oncology Biomarker Discovery

Takara Bio Europe, a wholly owned subsidiary of Takara Bio Inc., announces the launch of the Shasta™ Single-Cell System at the 2024 Human Cell A...

September 27, 2024 | Friday | News
Thermo Fisher Scientific Expands OSD Capabilities with $22 Million Investment to Accelerate Drug Development

To provide flexible and innovative solutions for early development challenges commonly faced by biotech and pharmaceutical companies, Thermo Fisher Scien...

September 27, 2024 | Friday | News
Emmes Secures Major NIH Contract to Lead Clinical Coordinating Center for National Institute on Drug Abuse Trials

Emmes, part of Emmes Group, announced they will provide a Clinical Coordinating Center for the NIH's National Institute on Drug Abuse Clinical Trials &nbs...

September 26, 2024 | Thursday | News
Eli Lilly CEO David Ricks Announces Major Expansion of India Research Hub, Poised to Transform Global Drug Innovation

Eli Lilly and Company (NYSE: LLY), a global leader in biopharmaceuticals, has announced plans to expand its research and development (R&D) center in ...

September 24, 2024 | Tuesday | News
Nxera Pharma Secures Japanese Approval for QUVIVIQ™ to Treat Insomnia Based on Positive Phase 3 Trial Results

The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3...

September 24, 2024 | Tuesday | News
Thermo Fisher's PPD Clinical Research Expands to GoCo Health Innovation City in Sweden

The PPD clinical research business joins GoCo Health Innovation City in Gothenburg, Sweden The PPD™ clinical research business of Thermo Fisher Sc...

September 19, 2024 | Thursday | News
Vidac Pharma Secures Broad U.S. Patent for Pioneering Cancer Treatment Mode of Action

Vidac Pharma Holdings Plc., a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments,  announces that the U...

September 19, 2024 | Thursday | News
BeiGene Secures Israeli Ministry of Health Approval for TEVIMBRA® in Treating Esophageal Squamous Cell Carcinoma

BeiGene, a global oncology company, announced that the Israeli Ministry of Health (IL MOH) has approved TEVIMBRA® (tislelizumab) as monotherapy for t...

September 18, 2024 | Wednesday | News
Immutep Presents Promising Phase IIb Trial Results of Efti and KEYTRUDA® at ESMO 2024

Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024 In patients with any PD-L1 expression (CPS ≥1), efti in co...

September 17, 2024 | Tuesday | News
MaxCyte and Kamau Therapeutics Partner to Advance Next-Gen Gene Therapies for Sickle Cell Disease

MaxCyte, Inc.,  a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and comme...

September 16, 2024 | Monday | News
CPC Introduces Innovative Aseptic Micro-Connector for Cell and Gene Therapy Freeze Cassettes

CPC (Colder Products Company), part of Dover  and a leading manufacturer of connection technologies used in biopharmaceutical processing, today...

September 12, 2024 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close